CClinicalTrials.gg
TerminatedNCT03348878THERMO-HTAUpdated Jun 23, 2022

Descriptive Study of Drug Compliance in Uncontrolled Hypertensive Patients

An interventional study of assessment of drug compliance in Uncontrolled Hypertension, sponsored by Hospices Civils de Lyon. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other

Why this study was terminated
only 4 patients
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Therapeutic compliance is defined as the degree of coincidence between a person's behavior and prescribing advice given by his or her physician. According to the World Health Organization (WHO), "insufficient adherence is the main reason why patients do not get all the benefits they could expect from their medicines. It causes medical and psychosocial complications, diminishes the quality of life of patients, increases the likelihood of drug resistance, and waste of resources. " In the case of certain conditions such as high blood pressure (hypertension), poor adherence increases the risk of stroke, acute coronary syndrome, and heart failure.

In patients with uncontrolled hypertension under treatment, the issue of therapeutic non-compliance should always be considered before considering the dose (supplemental drug) of antihypertensive therapy.

For each patient participating in the study, medication adherence (for one of the antihypertensive treatments) will be assessed for 2 months using an electronic pill. The antihypertensive treatments considered for the study belong to the following classes: diuretics, beta-blockers, calcium-blockers, ACE (angiotensin-converting enzyme) inhibitors, sartans.

Main objective: care objective: to provide physicians and patients with assistance in case of ineffectiveness or therapeutic escape in a chronic disease such as hypertension, by assessing the compliance profile of each patient.

Secondary objectives: to carry out a quantitative typology of drug adherence in patients with unbalanced HTA under treatment.

02

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

Keywords

  • drug compliance
  • hypertension
  • anti-hypertensive agents
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patient treated with diuretics and / or beta-blockers and / or calcium-blockers and / or ACE inhibitors and / or sartans
  • Holter blood pressure total average of 24h greater than 135/85 mmHg or a daytime average greater than 140/90 mmHg or a nighttime average greater than 125/75 mmHg.
  • informed consent given

Exclusion criteria

Exclusion Criteria:

  • Adults with severe hypertension (BP ≥ 180/110 mmHg) with or without organ failure requiring therapeutic adaptation
  • Adults unable to comply with study procedures
  • Patients who do not wish to receive generic drugs.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Other
    cohort of uncontrolled hypertensive patients

    Other: assessment of drug compliance

Interventions

  • Otherassessment of drug compliance

    assessment of drug compliance using electronic monitoring devices (2 months duration)

05

What researchers measure

Primary outcomes

  1. individual pattern of drug compliance

    compliance measurement using electronic monitoring devices

    Time frame: 2 months of follow-up

Secondary outcomes

  1. Percentage of Prescribed Dosing Days with Correct Intake

    The percentage of days with accurate dose intake is defined according to the reference: Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997 Jun;18(3):187-203.

    Time frame: 2 months of follow-up

  2. Percentage of Prescribed Dose Taken

    This measure, though often close to the previous one, focuses on the dose actually received and is defined according to the reference: Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997 Jun;18(3):187-203.

    Time frame: 2 months of follow-up

  3. Percentage of Drug Holidays

    We define a "drug holiday" as a period of one or more days without drug intake (that is, without MEMS (Medication Event Monitoring System) opening). The statistic counts the number of gaps among the prescribed days, ignoring the length of each individual gap, according to the reference: Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997 Jun;18(3):187-203.

    Time frame: 2 months of follow-up

  4. Time Variability in Drug Intake

    summary measures consider only the number of medication events each day, according to the reference: Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997 Jun;18(3):187-203.

    Time frame: 2 months of follow-up

06

Study locations

1 site
  • Hôpital Louis Pradel
    Bron, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03348878
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Nov 21, 2017
Start date
Dec 16, 2019
Primary completion
Mar 23, 2022
Completion
Mar 23, 2022
Last update
Jun 23, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion